Paul Herendeen, EVP and CFO at Valeant Pharmaceuticals International, Inc. (VRX), bought 30,000 shares at $16.10 ($483K) on 2018-03-13, disclosed to the SEC on 2018-03-13.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.10 | 15,000 | $242K | 50.0% |
| 2 | $16.10 | 15,000 | $242K | 50.0% |
| Total | $16.10 avg | 30,000 | $483K | 100% |
| Filing → |
| BHC | BUY | 2018-09-17 | $226K | — | Filing → |
| VRX | BUY | 2017-03-16 | $515K | — | Filing → |
| WCRX | SELL | 2013-03-01 | $63K | — | Filing → |